Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Reeves

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Oncologist|September 23, 2022
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted TherapyToni K Choueiri, Camillo Porta, Cristina Suárez, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 1, 2014
Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphomaJohn D Hainsworth, F Anthony Greco, Eric L Raefsky, et al.
Clinical Lung Cancer|May 5, 2010
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, Dana S Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma RegimensRuben Niesvizky, Ian W Flinn, Robert Rifkin, et al.
Nature Cancer|July 5, 2022
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancerLaura M Spring, Hyo Han, Minetta C Liu, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancerGerald S Falchook, James Reeves, Sunil Gandhi, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical Breast Cancer|October 9, 2012
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancerRachel Borson, Graydon Harker, James Reeves, et al.
Clinical Breast Cancer|August 30, 2016
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II StudyDenise A Yardley, James Reeves, E Claire Dees, et al.
JAMA Oncology|June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical TrialMiguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Oncologist|September 23, 2022
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted TherapyToni K Choueiri, Camillo Porta, Cristina Suárez, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 1, 2014
Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphomaJohn D Hainsworth, F Anthony Greco, Eric L Raefsky, et al.
Clinical Lung Cancer|May 5, 2010
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, Dana S Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma RegimensRuben Niesvizky, Ian W Flinn, Robert Rifkin, et al.
Nature Cancer|July 5, 2022
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancerLaura M Spring, Hyo Han, Minetta C Liu, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancerGerald S Falchook, James Reeves, Sunil Gandhi, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical Breast Cancer|October 9, 2012
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancerRachel Borson, Graydon Harker, James Reeves, et al.
Clinical Breast Cancer|August 30, 2016
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II StudyDenise A Yardley, James Reeves, E Claire Dees, et al.
JAMA Oncology|June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical TrialMiguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Pageof 4